admin – Page 5755 – Get News Story

US Insulated Bottles, Mugs, & Tumblers Market to Reach $748.17 Million by 2029, High Adoption of Personalization Creating Market Opportunities – Arizton

“U.S. Insulated Bottles, Mugs, & Tumblers Market Research Report by Arizton”

According to Arizton’s latest research report, the US insulated bottles, mugs, & tumblers market is growing at a CAGR of 4.27% during 2023-2029.

To Know More, Click: https://www.arizton.com/market-reports/united-states-insulated-bottles-mugs-and-tumblers-market

Report Summary        

Market Size (2029): $748.17 Million    

Market Size (2023): $582.28 Million   

CAGR (2023-2029): 4.27%   

Historic Year: 2020-2022   

Base Year: 2023   

Forecast Year: 2024-2029   

Market Segmentation: Product, Usage, Gender, Age Group, and Distribution Channel

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here:https://www.arizton.com/subscription              

Rising Demand for Personalized Insulated Bottles, Mugs, and Tumblers in the US Driven by Increased Disposable Income and Gifting Trends

The demand for personalized insulated bottles, mugs, and tumblers is escalating in the US, fueled by rising disposable income and their popularity as gifts. Customized bottles, which serve as ideal presents for corporate events, family, or friends, offer a personal touch that enhances their appeal. Consumers appreciate products that reflect their individuality, with options to choose logos, engravings, patterns, and colors that align with their personal styles.

US consumers are willing to pay a premium for customized items, highlighting their higher disposable income. Companies like CamelBak, Klean Kanteen, RTIC Outdoors LLC, MIRA Brands, Simple Modern, S’well, and Thermos L.L.C. are capitalizing on this trend by offering personalized solutions to attract customers.

Technological advancements and the expansion of the retail sector are key drivers behind the growing demand for personalized insulated products. Online platforms facilitate easier customization and broader market reach, while the latest technologies enable more detailed designs and quicker production times. Additionally, IT companies are increasingly seeking custom products for employee gifts, enhancing brand identity and organizational presence.

New Product Innovation

In 2023, the Hydro Flask a brand of Helen of Troy Limited introduced a first-of-its kind stainless steel bottle trade-in and recycling program, specifically designed to ensure old products are recycled efficiently and properly.
In 2023, Thermos LLC launched the Icon Series, featuring cold and hot beverage containers with a focus on grip and convenience.
In 2024, Yeti launched the new Big Wave Collection, offering new colors to attract consumers.
In 2024, CamelBak launched the Podium steel series, which is built to keep water cold for hours.

Competitive Overview

The US insulated bottles, mugs, and tumblers market is highly competitive, featuring both established brands and new entrants striving for market share. Established players are recognized for their high-quality, durable products and extensive range of insulated items.

New entrants are making their mark with colorful, stylish insulated bottles and a strong emphasis on sustainability. Many of these companies offer eco-friendly, BPA-free products and promote the use of reusable materials to help reduce plastic waste.

Manufacturers are investing in new technologies to enhance the functionality and performance of their products. Additionally, companies are leveraging social media advertising and targeted campaigns to increase their market presence.

Many brands sell their products directly to consumers through various online platforms and their own websites. Customization services are also offered to attract and retain customers.

Buy this Research @ https://www.arizton.com/market-reports/united-states-insulated-bottles-mugs-and-tumblers-market

Key Vendors

CamelBak
HAVI
Helen of Troy Limited
Klean Kanteen
MIRA Brands
Newell Brands
Simple Modern
S’well
Thermos L.L.C.
Yeti Holdings
BruMate Inc.
CORKCICLE
Igloo Products Corp.
MiiR
RTIC Outdoors LLC
Takeya USA Corporation
Trove Brands, LLC
Zojirushi
Cayman Fitness
Chilly’s
Custom Earth Promos
Fnova
Healthy Human, LLC
Ice Shaker
LAMOSE
LifeStraw
Nestle
Rehydrate Pro
RELYmedia
Steelys Drinkware
TERVIS TUMBLER COMPANY
TIGER CORPORATION
Tru Flask
Walmart

Segmentation & Forecast

Product
- Bottles
- Tumblers
- Mugs
Usage
- Water
- Beverages
Gender
- Females
- Males
Age
- Below 29
- 30 to 49
- 50 to 64
- 65 & Above
Distribution Channel
- Supermarkets & Hypermarkets
- Specialty Stores
- E-commerce
- Convenience Stores

Key Questions Answered in the Report:       

How big is the U.S. insulated bottles, mugs, & tumblers market?

What are the key trends in the U.S. insulated bottles, mugs, & tumblers market?

What is the growth rate of the U.S. insulated bottles, mugs, & tumblers market?

Who are the major players in the U.S. insulated bottles, mugs, & tumblers market?

Check Out Some of the Top Selling Reports of Your Interest:    

U.S. Baby Feeding Bottles Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-baby-feeding-bottles-market

U.S. Heating Pads Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/united-states-heating-pads-market

Why Arizton?                                      

100% Customer Satisfaction                                      

24×7 availability – we are always there when you need us                                      

200+ Fortune 500 Companies trust Arizton’s report                                      

80% of our reports are exclusive and first in the industry                                      

100% more data and analysis                                      

1500+ reports published till date                    

Post-Purchase Benefit                                  

1hr of free analyst discussion                                  

10% off on customization               

About Us:                                                                           

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                         

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                          

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707 
Country: United States
Website: https://www.arizton.com/market-reports/united-states-insulated-bottles-mugs-and-tumblers-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: US Insulated Bottles, Mugs, & Tumblers Market to Reach $748.17 Million by 2029, High Adoption of Personalization Creating Market Opportunities – Arizton

Refractories Market Size, Growth, Opportunities, Top Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2029

“Browse 323 market data Tables and 55 Figures spread through 282 Pages and in-depth TOC on “Refractories Market””

The Refractories Market is expanding due to the growth of the steel, cement, and glass industries. Asia-Pacific dominates with rapid industrialization, while Europe and North America emphasize high-performance materials and sustainability practices.

The global refractories market size is projected to grow from USD 34.3 billion in 2024 to USD 42.4 billion by 2029, at a CAGR of 4.4% during the forecast period. The refractories market is experiencing growth due to several key factors. Firstly, increasing industrialization, particularly in sectors such as steel, cement, and chemicals, is driving demand for refractory materials to withstand high temperatures and harsh operating conditions. Additionally, ongoing infrastructure development projects worldwide are fueling demand for construction materials like cement, which in turn boosts the need for refractories in cement production. Moreover, advancements in refractory technology are enhancing material performance and extending the lifespan of refractory linings, further driving market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222632393

A few of the major players are, RHI Magnesita (Austria), Vesuvius (UK), Krosaki Harima Corporation (Japan), Imerys (France), Shinagawa Refractories Co., Ltd. (Japan), Saint-Gobain (France), and Calderys (France). These players have implemented various growth strategies, such as acquisitions, investments, expansions, joint ventures, and partnerships to enhance their market shares and boost their product portfolios.

RHI Magnesita is a global leader in the refractories industry, formed by the merger of RHI AG and Magnesita Refratários SA. With a rich heritage spanning over a century, the company boasts unparalleled expertise in providing innovative refractory solutions to a wide range of industries worldwide, including steel, cement, non-ferrous metals, and more. Leveraging advanced technology and a robust global network, RHI Magnesita offers a comprehensive portfolio of high-quality refractory products and services, catering to the evolving needs of its diverse customer base. Its commitment to research and development, coupled with a focus on sustainability and operational excellence, positions RHI Magnesita at the forefront of the refractories market, driving growth and delivering value to its stakeholders.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222632393

Vesuvius, established in 1916 and headquartered in London, stands as a premier global provider of molten metal flow engineering solutions and advanced refractories. With a century-long legacy of innovation and expertise, Vesuvius serves diverse industries including steel, foundry, and glass. Their extensive portfolio and commitment to research and development empower them to deliver tailored solutions that optimize efficiency and enhance performance. Through their global presence and customer-centric approach, Vesuvius continues to drive advancements in molten metal flow control and refractory technology, supporting industries worldwide in achieving their operational excellence goals.

Krosaki Harima Corporation, founded in 1919 and headquartered in Tokyo, Japan, is a prominent player in the global refractories industry. With a rich history spanning nearly a century, the company has established itself as a leading manufacturer of high-quality refractory products and solutions. Serving a wide range of industries including steel, cement, and non-ferrous metals, Krosaki Harima Corporation is renowned for its commitment to innovation, quality, and customer satisfaction. Through its advanced research and development efforts, coupled with a focus on sustainability and technological excellence, the company continues to meet the evolving needs of its customers worldwide, solidifying its position as a key player in the refractories market.

The companies have initiated the following developments:

In January 2023, RHI Magnesita completed the acquisition of the Indian refractory business of Dalmia Bharat Refractories Limited (DBRL).
In March 2022, RHI Magnesita and the Horn & Co. Group signed a mutual agreement to merge their recycling endeavors in Europe, aiming to enhance the production, utilization, and availability of secondary raw materials for the European refractory industry.
In October 20232, Vesuvius acquired Bayuquan Magnesium Co (BMC), a top-tier basic monolithic refractory plant in China.
In December 2021, Vesuvius acquired the trade and assets of Universal Refractories Inc. (URI), a specialty refractory producer headquartered in Pennsylvania, USA.
In April 2024, Vesuvius fortified its presence in India by inaugurating a state-of-the-art flux manufacturing facility.
In May 2021, Krosaki Harima Corporation signed a partnership agreement with ArcelorMittal Refractories, based in Kraków, Poland, and part of the ArcelorMittal Group. This collaboration was done with the aim of optimizing production capacities and enhancing ArcelorMittal Refractories’ product portfolio.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=222632393

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/refractories-market-222632393.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Refractories Market Size, Growth, Opportunities, Top Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2029

The US Bone & Joint Health Supplements Market is Set to Reach $4.11 Billion by 2029, Shift Towards Natural and Plant-Based Products Sparks Boom in Market Opportunities – Arizton

“U.S. Bone And Joint Health Supplements Market Research Report by Arizton”

According to Arizton’s latest research report, the US bone & joint health supplements market is growing at a CAGR of 3.73% during 2023-2029.

To Know More, Click: https://www.arizton.com/market-reports/us-bone-and-joint-health-supplements-market

Report Summary       

Market Size (2029): $4.11 Billion   

Market Size (2023): $3.30 Billion  

CAGR (2023-2029): 3.73%  

Historic Year: 2020-2022  

Base Year: 2023  

Forecast Year: 2024-2029  

Market Segmentation: Product, Form, Gender, End-User, and Distribution Channel

The US Bone & Joint Health Supplements Market Booms with Shift Towards Natural, Plant-Based Products and Popularity of Gummies

The US bone and joint health supplements market is experiencing substantial growth, driven by evolving consumer preferences and an increased focus on preventive healthcare. A notable trend is the shift towards natural and plant-based ingredients, with consumers seeking products that are perceived as safer and more environmentally friendly.

Manufacturers are responding to this demand by incorporating natural sources of calcium, vitamins, and other essential nutrients into their supplements. Popular plant-based ingredients now include algae-derived calcium and herbal extracts.

The gummies segment is also expanding rapidly, thanks to the introduction of diverse flavors and formulations that appeal to a wider audience. Gummies are favored for their convenience, taste, and ease of consumption, particularly among children and older adults who may struggle with pills. The aging US population is a key driver of the market, as older adults are more prone to osteoporosis and arthritis. This has led to the development of supplements tailored to support bone density and joint health in older consumers, addressing age-related issues.

Advancements in nutritional science and supplement formulation are contributing to market growth. Enhanced bioavailability, innovative delivery systems, and synergistic ingredient combinations make supplements more effective and attractive. Consumers, now more aware of micronutrient deficiencies, are increasingly seeking products that help fill nutritional gaps, especially those vital for bone density and joint function.

Key Development

In 2023, Voltaren, a brand under Haleon, introduced two new non-prescription pain supplements, joint comfort and movement and joint health and bone strength dietary supplements, aimed at improving joint health and mobility. These products feature natural, scientifically backed ingredients designed to protect joint tissue and cartilage, promote healthy inflammatory responses post-exercise, and support healthy aging, according to the company.
In 2022, the vitamins and supplements brand of Nestlé, Puritan’s Pride announced the launch of an affordable Personalized Vitamin Packs subscription program. Customers can take a five-minute quiz on the company’s website to receive a personalized regimen of vitamins and supplements. These customized daily packs are then conveniently delivered to customers’ doorsteps each month.

Market Segmentation

Product Type Insights:

In the U.S. bone and joint health supplements market, the minerals segment commands the largest market share in 2023. Minerals are essential for bone and joint health and are a fundamental component of many dietary supplements aimed at supporting these areas. Calcium, magnesium, and phosphorus are the primary minerals featured in these supplements, playing crucial roles in maintaining, developing, and repairing bones and joints. Their effectiveness is well-supported by scientific research, and they are generally well-tolerated, making them popular choices for individuals looking to support their musculoskeletal health.

Form Type Insights:

The market for bone and joint health supplements in the U.S. is also segmented by form type, including tablets, capsules & softgels, gummies, liquids & powders, and others. The gummies segment is experiencing significant growth, with the highest compound annual growth rate (CAGR) during the forecast period. This surge in popularity is driven by shifting consumer preferences, product innovations, and effective marketing strategies. Gummies are especially appealing due to their ease of consumption, which is advantageous for those who have difficulty swallowing pills or capsules. Their convenience, as they can be taken without water and are portable, makes them particularly attractive to older adults and children—key demographics for these supplements.

Buy this Research @ https://www.arizton.com/market-reports/us-bone-and-joint-health-supplements-market

Key Vendors

Amway
Kirkland Signature
Bayer AG
Haleon
Herbalife
Nature’s Sunshine Products
Nestle
Procter & Gamble
NOW Foods
Reckitt Benckiser Group
Better Being
Dr. Willmar Schwabe
GNC Holdings
Hi-Health
Isagenix
Life Extension
Nature’s Craft
Otsuka Pharmaceutical
Vytalogy Wellness
Shaklee
Church & Dwight
Unilever
BioTRUST Nutrition
Walmart
Arazo Nutrition
NATURELO
BASF SE
Bluebonnet Nutrition
Country Life
Enzymedica
Gaia Herbs
Hi-Tech Pharmaceuticals
Irwin Naturals
Kindomway Nutrition
mindbodygreen
Natural Immunogenics
H&H Group
NATURAL ORGANICS
Nordic Naturals
Orphic Nutrition
Solara Labs
Standard Process
Vimerson Health
Walgreens
Wellbeing Nutrition
Wild Nutrition
Bio Island
A&Z Pharmaceutical

Segmentation & Forecast

Product
- Vitamins
- Minerals
- Omega-3
- Glucosamine & Chondroitin
- Others
Form
- Tablets
- Capsules & Softgels
- Gummies
- Liquids & Powders
- Others
Gender
- Male
- Female
End-User
- Pediatric
- Adults
Distribution Channel
- Supermarket & Hypermarkets
- Pharmacies & Drugstores
- Specialty Stores
- E-Commerce
- Others

Key Questions Answered in the Report:      

How big is the U.S. bone and joint health supplements market?

What are the key U.S. bone and joint health supplements market trends?

What is the growth rate of the U.S. bone and joint health supplements market?

Who are the major players in the U.S. bone and joint health supplements market?

Check Out Some of the Top Selling Reports of Your Interest:          

U.S. Weight Loss Dietary Supplements Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-weight-loss-dietary-supplements-market

U.S. Maternal Supplements Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-maternal-supplements-market

Why Arizton?                                     

100% Customer Satisfaction                                     

24×7 availability – we are always there when you need us                                     

200+ Fortune 500 Companies trust Arizton’s report                                     

80% of our reports are exclusive and first in the industry                                     

100% more data and analysis                                     

1500+ reports published till date                   

Post-Purchase Benefit                                 

1hr of free analyst discussion                                 

10% off on customization              

About Us:                                                                          

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707
Country: United States
Website: https://www.arizton.com/market-reports/us-bone-and-joint-health-supplements-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The US Bone & Joint Health Supplements Market is Set to Reach $4.11 Billion by 2029, Shift Towards Natural and Plant-Based Products Sparks Boom in Market Opportunities – Arizton

The Enduring Legacy of Edward Boginsky: Master of Fine Art Printing

Born in 1967 in Chernivtsi, Ukraine, Edward Boginsky began this path that would lead him to leave a trace in the domain of fine arts and fashion printing. Nevertheless, Boginsky decided to leave the traditional printing family business and embark on a new journey. In 1989, he established his own print shop located in Downtown Manhattan, New York, which specializes in new approaches to fine art and fashion printmaking.

During the period after 1990, Boginsky’s shop received much popularity and fame for offering a fusion of modern and traditional printing techniques. This blend not only made his work unique but also ensured that he worked with highly reputable fashion photographers, designers, and even tycoons such as Tom Ford and David Raccuglia.

Through his passion and hard work together with creativity in the printing business, Boginsky was awarded the Masters of Fine Art Printing. His work was not just about printing; it was so much more than one could ever imagine it to be. Anyone who was lucky to associate with him or come across his work could easily notice the zeal and hard work he invested into every piece.

However, the events of September 11 introduced a tragic note in Boginsky’s life. The impact on Manhattan and its community led him to make a significant decision: he left Manhattan and, over the years, faded out of the popular spotlight. Edward Boginsky decided to withdraw from the art and printing business and live a more unassuming life since his earlier days were filled with constant attention from the public.

Today, the world can be truly benefited from the work of Edward Boginsky as it is both deep and inspiring. Great techniques and his artistic work is still fascinating and inviting people to think inspiring a new generation, which might never had met him before the world of digital technologies. While he has taken a decision to stay out of the public eye his works in the field of art of printing will forever be etched in history. He wishes to motivate the next generation of artists and printers to create and follow their passion like he did.

If you wish to know more about Edward Boginsky, his work, his list of clients, and the accolades he has received throughout the years, please go to Edward Boginsky. Here, it is possible to learn more about the work of Edward Boginsky as one of the first fine art printers and consider his contribution to the development of art and visual culture today.

Edward Boginsky may have pulled himself out from the world that he once changed but his art remains to be a powerful tool that can touch and influence the hearts and minds that come across it, thus remaining as a proof of his creativity and innovation.

Media Contact
Company Name: Edward Boginsky
Contact Person: Edward Boginsky
Email: Send Email
Country: United States
Website: https://www.edwardboginsky.net/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Enduring Legacy of Edward Boginsky: Master of Fine Art Printing

Industrial Batteries Market Analysis, Opportunities, Growth, Trends, Top Companies, Regional Graph, Key Segments, and Forecast to 2029

“Browse 228 market data Tables and 51 Figures spread through 250 Pages and in-depth TOC on “Industrial Batteries Market””

The Industrial Batteries Market is growing due to increased demand in sectors like renewable energy and logistics. Asia-Pacific leads with rapid industrialization, while North America and Europe focus on sustainable energy storage solutions.

The global Industrial Batteries market is projected to grow from USD 21.2 billion in 2024 to USD 34.7 billion by 2029, at a CAGR of 10.3% during the forecast period. The growth of this market is attributed to rising adoption of lithium-ion batteries in the renewable energy sector and increasing demand for grid energy storage systems owing to ongoing grid modernization.

Companies such as Enersys (US), C&D Technologies, Inc. (US), GS Yuasa International Ltd. (Japan), Exide Industries Ltd. (India) and Leoch International Technology Limited Inc (China) fall under the winners’ category. These are leading players in the Industrial Batteries market globally. These players have adopted the strategies of acquisitions, expansions, partnerships, and investments to increase their market shares.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36754108

Enersys

Enersys is a manufacturer of industrial batteries. The company offers its products through various segments including motive power batteries (for forklifts, material handling equipment etc.), energy system batteries (for data centers, telecom etc.), and specialty batteries for various niche applications. It offers services that include designing, building, installing, and maintaining battery systems. It offers its products in different industrial uses including communications networks, the power of 5G, logistics & warehousing, transportation, cable broadband, data centers, industrial power & utilities, aerospace & defense, safety & security, and medical.

It has a global presence with manufacturing facilities in China, Europe, US, & Oceania and serves customers in over 100 countries. It also has regional headquarters in Europe and Asia. Alpha Technologies Services, Inc., NorthStar Battery, Odyssey Battery, ICS Industries, and Purcell Systems are the subsidiaries of Enersys

C&D Technologies, Inc.

C&D Technologies, Inc. is a manufacturer of energy storage solutions and services for various applications, including uninterruptible power supply (UPS), telecommunications, utility, cable, broadband, renewable energy markets. The company provides solutions to different sectors including data centers/UPS, energy and power infrastructure, renewable energy, telecommunications, government and electric vehicles.

The company manufactures two types of batteries including Flooded (VLA) and VRLA. The company has manufacturing facilities located in China, Mexico, and US. The company also has distributors in US, Canada, Europe, Latin America, Africa, Middle East, Asia. It acquired Trojan Battery Company in 2018 which is a manufacturer of deep-cycle batteries for motive and solar applications. Motive products are manufactured under the Trojan brand including, power golf cars, PTVs, EVs, RVs, boats, aerial lifts, and floorcare machines. The company also has two advanced research and development facilities located in the US and offices in Europe and Asia.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=36754108

Exide Industries Ltd.

Exide Industries Ltd. is an Indian Multinational storage battery manufacturing company. It provides lead-acid storage batteries and power storage solutions in India. It manufactures batteries ranging from 2.5Ah to 20,600Ah capacity, catering to various applications. Its products are applicable in diverse sectors, including automotive, power, telecom, infrastructure, computer, railways, mining and defense sector. The company has nine factories located all over India, out of which 7 factories are dedicated to Battery manufacturing and other 2 are manufacturing Home UPS Systems. It has manufacturing facilities 2 in West Bengal, 1 in Haryana, 3 in Maharashtra, 1 in Tamil Nadu, and 2 in Uttarakhand.

The company sells its products under various brands namely EXIDE, CHLORIDE, CEIL, INDEX, SF SONIC, and DYNEX. The company has a global presence in more than 50 countries. It also offers solutions in areas of equipment selection, battery sizing, optimum room layout, installation, operation and maintenance. The company has in house R&D Centre located in West Bengal, India.

GS Yuasa International Ltd.

GS Yuasa International Ltd. manufactures and sells automotive batteries, industrial batteries, power supply systems, switch gear, and other electrical equipment. The company also has subsidiaries including GS Yuasa Battery Ltd., GS Yuasa Energy Co., Ltd, GS Yuasa Technology Ltd., and Blue Energy Co., Ltd. GS Yuasa Corporation is the holding company for GS Yuasa International Ltd. The company has manufacturing facilities in Gunma, Kyoto, Shiga, & Saitama and has offices in city of Tokyo, Hokkaido, Miyagi, Aichi, Osaka, Hiroshima, and Fukuoka.

The company operates under business segments including Automotive Batteries (Overseas), Industrial Batteries & Power Supply Systems, Automotive batteries (Japan), Automotive Lithium-ion Batteries, specialized batteries and others. It marks its global presence in the US, Europe, East Asia, Asia & Oceania.

Leoch International Technology Limited Inc

Leoch International Technology Limited Inc is a Chinese Battery Manufacturing company. The company provides lead-acid and lithium batteries. The company operates through two business segments that are power solutions business and recycled lead business. The company has four product categories including Lithium Solutions, Network Power, Transportation, and Motive Power. The company serves its products and services to various industries such as Energy Storage Systems, Telecommunication & Data Center Power Solutions, Starting Power Solutions, Motive Power Solutions, Medical, Renewable energy and Battery Recycling. It has more than 10 manufacturing facilities and serves clients in more than 130 countries and regions worldwide.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=36754108

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Industrial Batteries Market Analysis, Opportunities, Growth, Trends, Top Companies, Regional Graph, Key Segments, and Forecast to 2029

Postherpetic Neuralgia Pipeline, Preclinical and Discovery Stage Products, Companies 2024

DelveInsight’s, “Postherpetic Neuralgia Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Postherpetic Neuralgia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Postherpetic Neuralgia Pipeline Outlook

Key Takeaways from the Postherpetic Neuralgia Pipeline Report

July 2024:- Merz Therapeutics GmbH- A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury.
June 2024:- iN Therapeutics Co. Ltd.- A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers.
DelveInsight’s Postherpetic Neuralgia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Postherpetic Neuralgia treatment.
The leading Postherpetic Neuralgia Companies such as Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Cannabinoid Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.
Promising Postherpetic Neuralgia Therapies such as AJH-2947 100 mg (SAD), iN1011-N17 HCl Suspension (Part 1), and others.

Stay ahead with the most recent pipeline outlook for Postherpetic Neuralgia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postherpetic Neuralgia Treatment Drugs

Postherpetic Neuralgia Emerging Drugs Profile

HSK16149: Haisco Pharmaceutical Group

HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with Postherpetic Neuralgia.

LX9211: Lexicon Pharmaceuticals

LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 and another development candidate were discovered by scientists working within Lexicon’s drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.

Explore groundbreaking therapies and clinical trials in the Postherpetic Neuralgia Pipeline. Access DelveInsight’s detailed report now! @ New Postherpetic Neuralgia Drugs

Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Postherpetic Neuralgia Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Unveil the future of Postherpetic Neuralgia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Postherpetic Neuralgia Market Drivers and Barriers

Scope of the Postherpetic Neuralgia Pipeline Report

Coverage- Global
Postherpetic Neuralgia Companies- Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Cannabinoid Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.
Postherpetic Neuralgia Therapies- AJH-2947 100 mg (SAD), iN1011-N17 HCl Suspension (Part 1), and others.
Postherpetic Neuralgia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Postherpetic Neuralgia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Postherpetic Neuralgia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Postherpetic Neuralgia Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Postherpetic Neuralgia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Postherpetic Neuralgia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
HSK16149: Haisco Pharmaceutical Group
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
LX9211: Lexicon Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
AAT 730: Oxford Cannabinoid Technologies
Drug profiles in the detailed report…..
Inactive Products
Postherpetic Neuralgia Key Companies
Postherpetic Neuralgia Key Products
Postherpetic Neuralgia- Unmet Needs
Postherpetic Neuralgia- Market Drivers and Barriers
Postherpetic Neuralgia- Future Perspectives and Conclusion
Postherpetic Neuralgia Analyst Views
Postherpetic Neuralgia Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postherpetic Neuralgia Pipeline, Preclinical and Discovery Stage Products, Companies 2024

Major Depressive Disorder Pipeline Drugs, FDA Approvals, Companies 2024 | GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada

DelveInsight, “Major Depressive Disorder Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Major Depressive Disorder Pipeline Outlook

Key Takeaways from Major Depressive Disorder Pipeline Report

August 2024:- Relmada Therapeutics Inc.- A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT). This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder in patients with inadequate response to ongoing background antidepressant treatment. Eligible patients will continue to take their background antidepressant therapy and be randomized in a 1:1 ratio to treatment with REL-1017 or placebo for a 4 week treatment period.
July 2024:- Biohaven Therapeutics Ltd.- A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder. The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD).
July 2024:- Sirtsei Pharmaceuticals, Inc.- A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder. This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
The leading companies working in the Major Depressive Disorder Market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.

Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Treatment Drugs

Major Depressive Disorder Emerging Drugs Profile

SAGE-217: Sage Therapeutics

SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).

REL-1017: Relmada Therapeutics, Inc

REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.

Seltorexant: Minerva Sciences

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

SP-624: Sirtsei Pharmaceuticals, Inc.

SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.

SPL026: Small Pharma

SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

PDC-1421: BioLite Inc

PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Major Depressive Disorder Drugs

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Subcutaneous
Intravenous
Intramuscular

Major Depressive Disorder Products have been categorized under various Molecule types such as

Bispecific Antibody
Peptides
Small molecule
Gene therapy

Unveil the future of Major Depressive Disorder Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Major Depressive Disorder Market Drivers and Barriers

Scope of the Major Depressive Disorder Pipeline Report

Coverage- Global
Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
Major Depressive Disorder Pipeline Therapies- Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.

Get the latest on Major Depressive Disorder Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Major Depressive Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Major Depressive Disorder – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
SAGE-217: Sage Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SP-624: Sirtsei Pharmaceuticals, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SPL026: Small Pharma
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Major Depressive Disorder Pipeline Drugs, FDA Approvals, Companies 2024 | GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada

Multiple Myeloma Pipeline Outlook 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2024” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Multiple Myeloma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Multiple Myeloma Pipeline Outlook

Key Takeaways from the Multiple Myeloma Pipeline Report

August 2024:- Bristol-Myers Squibb- A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2. The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
August 2024:- Celgene– A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM).
August 2024:- AbbVie– A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study). Multiple myeloma (MM) is a cancer of the blood’s plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure.
DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
The leading Multiple Myeloma Companies working in the market include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
Promising Multiple Myeloma Pipeline Therapies in the various stages of development include TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Stay ahead with the most recent pipeline outlook for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Multiple Myeloma Treatment Drugs

Multiple myeloma Emerging Drugs Profile

Zevorcabtagene Autoleucel: Carsgen Therapeutics

Zevorcabtagene Autoleucel (Zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product candidate against B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM). In October 2022, China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and has granted the priority review for zevor-cel. Zevor-cel is expected to be approved by the NMPA for the treatment of R/R MM at the end of 2023 or the beginning of 2024. In January 2023, CARsgen and Huadong Medicine entered into a collaboration agreement for the commercialization of CARsgen’s lead drug candidate, zevor-cel, in mainland China. Since reaching the agreement, teams from CARsgen and Huadong Medicine have been working together closely to implement this collaboration and prepare for the approval and commercialization of zevor-cel in China.

Descartes 08: Cartesian Therapeutics

Descartes-08 is an autologous BCMA-targeting RNA-modified CAR T-cell therapy. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In early-stage clinical studies, Descartes-08 has been safe and well-tolerated in patients with MG and multiple myeloma. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple Myeloma.

GC012F: Gracell Biotechnology Shanghai Co., Ltd.

GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the United States and a Phase 1/2 clinical trial in China is to be commenced imminently.

CID-103: CASI Pharmaceuticals

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments. Preclinical data of CID-103 demonstrates enhanced activity against a broad array of malignancies which express CD38 and demonstrates a better preclinical safety profile when compared to other CD38 mAbs. These attributes offer the potential for accelerated development and regulatory review, including rapid advancement into earlier lines of therapy. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

STI-1492: Sorrento Therapeutics

STI-1492 is a therapeutic candidate developed by Sorrento Therapeutics for the treatment of relapsed or refractory multiple myeloma. It is an allogeneic, off-the-shelf therapy that involves the administration of Anti-CD38 A2 Dimeric Antigen Receptor T (DAR-T) cells through a single intravenous infusion. The therapy is currently being evaluated in a phase 1b, open-label, dose-escalation study involving subjects with relapsed or refractory multiple myeloma. CD38 is a transmembrane glycoprotein present on various immune cells and hematologic malignancies, and its expression has been associated with poor prognosis. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

Explore groundbreaking therapies and clinical trials in the Multiple Myeloma Pipeline. Access DelveInsight’s detailed report now! @ New Multiple Myeloma Drugs

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Multiple Myeloma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Multiple Myeloma Market Drivers and Barriers

Scope of the Multiple Myeloma Pipeline Report

Coverage- Global
Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Get the latest on Multiple Myeloma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Multiple Myeloma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Multiple myeloma Executive Summary
Multiple myeloma Overview
Multiple myeloma Pipeline Therapeutics
Multiple myeloma Therapeutic Assessment
Multiple myeloma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Venetoclax: AbbVie
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PHE885: Novartis
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ONC 201: Oncoceutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TNB 383B: TeneoBio
Drug profiles in the detailed report…..
Inactive Products
Multiple myeloma Companies
Multiple myeloma Products
Multiple myeloma Unmet Needs
Multiple myeloma Market Drivers and Barriers
Multiple myeloma Future Perspectives and Conclusion
Multiple myeloma Analyst Views
Multiple myeloma Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Pipeline Outlook 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics

Physical Security Market Trends, Size, Top Key Players, Industry Analysis, Advance Technology, Future Development & Forecast – 2028

“Johnson Controls (Ireland), Bosch Building Technology (Germany), Honeywell (US), ADT (US), Cisco (US), Telus (Canada), Wesco (US), Genetec (Canada), HID Global (US), Pelco (US), Hikvision (China), Gallagher (New Zealand), Secom (Japan), Allied Universal (US), Zhejiang Dahua Technology (China), Axis communications (Sweden).”

Physical Security Market by Component, System (Physical Access Control System, Video Surveillance System, and Perimeter Intrusion Detection and Prevention), Service, Organization Size, Vertical (BFSI and Healthcare) and Region – Global Forecast to 2028.

The global physical security market size is projected to grow from USD 110.2 billion in 2023 to USD 136.9 billion by 2028 at a Compound Annual Growth Rate (CAGR) of 4.4% during the forecast period. The expansion of the physical security market is being propelled by Rising instances of terrorist activities and security breaches to physical systems.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1014

Based on services, the managed services segment is expected to grow at a higher CAGR during the forecasted period.

Effective management of business processes in contemporary corporate contexts requires the adoption of proven approaches across organizations. Organizations are forced to outsource some tasks since maintaining internal services requires more time, there aren’t enough resources, and it costs more money. Managed service providers guarantee the protection of important corporate data as well as the efficiency of business processes. Customers are assisted by managed service providers to maintain their hardware, software, physical security systems, and solutions up to date with the most recent improvements. Customers’ internal capacities are increased when MSPs protect their physical assets and IT system assets.

By managed services, the access control as a services segment is expected to hold the largest market size during the forecast period.

Access Control as a Service (ACaaS) is a cloud-based, service-oriented architecture that supports access control models in new-age operating systems. It integrates cloud-hosted and managed solutions with various on-site access control systems. The demand for ACaaS is rising across verticals because of its distinguishing characteristics, such as remote management, scalability, real-time control, data security, and secure communications. The importance of access control lies in its ability to bolster the overall security posture of an organization, providing a flexible and scalable solution to meet specific needs, enhance operational efficiency, and ensure the safety of personnel and valuable assets.

By region, Asia Pacific is expected to grow at the highest CAGR during the forecast period.

Due to the region’s rising crime rate, physical security solutions are quickly gaining popularity across Asia and the Pacific. Security-related worries are becoming more prevalent, particularly in China, Malaysia, Australia, and India. Therefore, the government of several of these nations is encouraging the implementation of physical security measures to manage such a circumstance. Governments in the Asia Pacific are investing a significant portion of their federal budgets in developing security tools, which is expected to drive the adoption of physical security solutions. Moreover, the region is witnessing the large development of smart cities. Countries such as China have invested heavily in smart city programs. It is planning to spend USD 39 billion on smart cities. Smart cities heavily rely on physical security solutions, which is also driving the physical security market in the region.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1014

Unique Features in the Physical Security Market

The physical security market is rapidly evolving with the integration of advanced surveillance technologies. High-definition (HD) and ultra-high-definition (UHD) cameras, along with thermal imaging and night vision capabilities, offer unparalleled clarity and coverage.

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the physical security landscape. These technologies enable intelligent video analytics, facial recognition, and behavior analysis.

The Internet of Things (IoT) is playing a significant role in modern physical security solutions. Integration with IoT devices such as smart locks, sensors, and alarms allows for comprehensive security systems that provide real-time alerts and remote monitoring capabilities.

Cloud-based security solutions offer significant advantages in terms of scalability, accessibility, and cost-effectiveness. These solutions allow for centralized management and storage of security data, enabling real-time access and analysis. Cloud platforms also facilitate easier integration with other security systems and provide robust backup and disaster recovery options.

Modern access control systems have evolved beyond traditional key and card systems. Biometric authentication methods, such as fingerprint, iris, and facial recognition, provide higher levels of security and convenience.

Major Highlights of the Physical Security Market

The physical security market is witnessing significant technological advancements in surveillance systems. High-definition (HD) and ultra-high-definition (UHD) cameras, along with thermal imaging and night vision capabilities, are becoming standard. These technologies provide exceptional clarity and coverage, enabling detailed monitoring and recording even in challenging conditions, thereby enhancing overall security measures.

Artificial Intelligence (AI) and Machine Learning (ML) are transforming the physical security sector. These technologies enable intelligent video analytics, facial recognition, and behavior analysis. AI-powered systems can detect unusual activities, identify potential threats in real-time, and significantly reduce false alarms, thereby improving the accuracy and efficiency of security operations.

The integration of Internet of Things (IoT) devices with physical security systems is a major highlight. Smart locks, sensors, and alarms, connected through IoT, provide real-time alerts and remote monitoring capabilities. This interconnected approach ensures a comprehensive security environment that enhances responsiveness and situational awareness.

Cloud-based security solutions are gaining popularity due to their scalability, accessibility, and cost-effectiveness. These solutions offer centralized management and storage of security data, enabling real-time access and analysis. Cloud platforms facilitate easier integration with other security systems and provide robust backup and disaster recovery options.

Modern access control systems have evolved to include biometric authentication methods such as fingerprint, iris, and facial recognition. These systems provide higher levels of security and convenience. Additionally, mobile-based access control solutions allow users to manage access via smartphones, offering flexibility and reducing the need for physical credentials.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=1014

Top Companies in the Physical Security Market

Johnson Controls (Ireland), Bosch Building Technology (Germany), Honeywell (US), ADT (US), Cisco (US), Telus (Canada), Wesco (US), Genetec (Canada), HID Global (US), Pelco (US), Hikvision (China), Gallagher (New Zealand), Secom (Japan), Allied Universal (US), Zhejiang Dahua Technology (China), Axis communications (Sweden), Hanwha Vision America (US), Teledyne FLIR (US), Hexagon AB (Sweden), General Dynamics (US), BAE Systems (UK), Huawei (China), NEC (Japan), Qognify (US), SmartCone Technology (Canada), Verkada (US), IOTAS (US), Cloudastructure (US) are the key players and other players in the physical security market.

Cisco Systems, Inc. is a renowned multinational technology company headquartered in San Jose, California. Founded in 1984, Cisco has become a global leader in the networking hardware, software, and telecommunications equipment industries. The company’s main areas of concentration include developing, producing, and marketing a wide variety of goods and services that enable seamless data, voice, and video communication over different networks. With its range of products, including routers, switches, security solutions, teamwork tools, and cloud-based services, Cisco has played a key role in the growth of the Internet and the development of contemporary networking technology. With a strong focus on innovation, Cisco keeps reshaping the digital environment and enabling people, organizations, and governments to connect, cooperate, and prosper in the digital era.

The business focuses on offering IP-based products and services to the Information and Communication Technology (ICT) sector. Networking, wireless and mobile, security, collaboration, data center, analytics, video, Internet of Things, and software are among the products and services it provides. Its wide range of physical security products includes IP cameras, video surveillance platforms, software, access control, and incident response. Its ongoing investment in R&D, which allows advancements in high-quality products and services, places it among the best physical security firms. Technical support and cutting-edge services are among its service offerings.

Johnson Controls International plc is a leading global provider of diverse technology and multi-industrial products. Johnson Controls has a long history of developing ground-breaking solutions for the construction, energy-efficient, and automotive sectors. The company offers products and services pertaining to security, fire detection, suppression, and life safety. It sells physical security products and services under the following brand names: Tyco, SimplexGrinnell, Sensormatic, Ansul, Simplex, Scott and ADT, Software House, Visonic, Chemguard, and Exacq. Through the global products segment, the company designs manufactures and sells fire protection, security, and life safety products, including intrusion security systems, anti-theft devices, breathing apparatus, and access control and VMS, for its customers in the commercial, industrial, retail, residential, education, and government sectors worldwide. This segment also includes the products installed and serviced by its integrated solutions and services. Some of the key subsidiaries of the company in the physical security market are ADT Security Services S.A. (Argentina), Tyco Fire & Security (Australia), and Exacq Technologies, Inc. (US).

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Physical Security Market Trends, Size, Top Key Players, Industry Analysis, Advance Technology, Future Development & Forecast – 2028

The US Vitamin Gummies Market to Hit $3.47 Billion by 2029, E-Commerce Distribution Channel Creating Market Expansion – Arizton

“U.S. Vitamin Gummies Market Research Report by Arizton”

 According to Arizton’s latest research report, the US vitamin gummies market is growing at a CAGR of 6.94% during 2023-2029.

To Know More, Click: https://www.arizton.com/market-reports/united-states-vitamin-gummies-market

Report Summary       

Market Size (2029): $3.47 Billion   

Market Size (2023): $2.32 Billion  

CAGR (2023-2029): 6.94%  

Historic Year: 2020-2022  

Base Year: 2023  

Forecast Year: 2024-2029  

Market Segmentation: Source, Gender, End-User, Application, and Distribution Channel

The U.S. vitamin gummies market has seen significant growth, with more consumers favoring gummy vitamins over traditional pill forms. This expansion is largely driven by increased health awareness and the rising popularity of convenient supplement options. The market is also experiencing a surge of innovation as companies work to meet changing consumer preferences and stand out in a competitive landscape. Vendors are introducing novel and exotic flavors to enhance the appeal of gummy vitamins. For example, in March 2024, the supplement brand Nature Made released a limited-edition pickle-flavored version of its multivitamin gummies, inspired by the growing popularity of pickles and pickleball. Additionally, companies are creating gummy vitamins that offer multiple benefits in a single product, such as blends of multivitamins designed to support immunity, energy, and overall wellness. There is a growing consumer demand for personalized nutrition solutions that cater to individual health needs and genetic profiles. Brands are also innovating with new formulations that incorporate additional nutrients and address specific health concerns, such as immune support, sleep aids, and beauty benefits. The trend towards natural and organic ingredients continues to rise, with many brands emphasizing non-GMO, gluten-free, and vegan options.

Key Development

In February 2024, Nature Made, a leading national brand in vitamins and supplements, announced the expansion of its multivitamin portfolio. It introduced the Nature Made Advanced Multivitamin Gummies, a new line of easily consumable gummies designed to address common dietary deficiencies.
In 2023, SmartyPants Vitamins launched a revamped version of its gummy products line, formulated without gelatin. These new products, including kids, teenagers, and Women’s multivitamin gummies with fresh flavors, made their debut in Walmart stores nationwide.

E-Commerce Segment Growth in Vitamin Gummies Market

The e-commerce segment is demonstrating remarkable growth as a distribution channel, boasting the fastest-growing compound annual growth rate (CAGR) during the forecast period. This expansion is largely driven by the ease of access to a wide range of brands and products, as well as the availability of customer reviews and ratings that assist consumers in making informed purchasing decisions.

The landscape of distribution channels for vitamin gummies in the U.S. has evolved significantly, with online retail platforms and Direct-to-Consumer (D2C) strategies becoming increasingly important. These channels have been instrumental in the growth and widespread adoption of vitamin gummies, addressing the rising demand for convenient and enjoyable nutritional supplements.

Major online retail platforms such as Amazon, Walmart, and Target play a crucial role in this sector. They offer extensive reach and convenience, enabling consumers to buy vitamin gummies from the comfort of their homes. The robust logistics networks and prime membership benefits provided by these platforms, including expedited and often same-day delivery, significantly enhance customer satisfaction and drive the growth of the e-commerce segment.

Buy this Research @ https://www.arizton.com/market-reports/united-states-vitamin-gummies-market

Key Vendors

Amway
Bayer
Church & Dwight
Dr. Willmar Schwabe
Haleon
Nestle
Pharmavite
Procter & Gamble
Reckitt Benckiser Group
Unilever
Amazon
NATURELO
GNC Holdings
Kirkland Signature
Nature’s Craft
Nordic Naturals
Shaklee
Hero Nutritionals
Vytalogy Wellness
Walmart
Country Life
Dollar General
Enzymedica
Hi-Health
Doctor’s Best
NATURAL ORGANICS
Nature’s Sunshine Products
Orphic Nutrition
SugarbearPRO
Vegums
Walgreens
Herbaland
Zanon

Segmentation & Forecast

Source
- Plant-based
- Animal-based
Gender
- Male
- Female
End-User
- Pediatric
- Adult
Application
- General & Immune Health
- Energy & Weight Management
- Bone & Joint Health
- Others
Distribution Channel
- Pharmacies & Drugstores
- Supermarket & Hypermarkets
- E-Commerce
- Specialty Stores
- Others

Key Questions Answered in the Report:      

How big is the U.S. vitamin gummies market?

What are the key drivers of the U.S. vitamin gummies market?

What is the growth rate of the U.S. vitamin gummies market?

Who are the major players in the U.S. vitamin gummies market?

Check Out Some of the Top Selling Reports of Your Interest:          

U.S. Weight Loss Dietary Supplements Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-weight-loss-dietary-supplements-market

U.S. Maternal Supplements Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/us-maternal-supplements-market

Why Arizton?                                     

100% Customer Satisfaction                                     

24×7 availability – we are always there when you need us                                     

200+ Fortune 500 Companies trust Arizton’s report                                     

80% of our reports are exclusive and first in the industry                                     

100% more data and analysis                                     

1500+ reports published till date                   

Post-Purchase Benefit                                 

1hr of free analyst discussion                                 

10% off on customization              

About Us:                                                                          

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707  
Country: United States
Website: https://www.arizton.com/market-reports/united-states-vitamin-gummies-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The US Vitamin Gummies Market to Hit $3.47 Billion by 2029, E-Commerce Distribution Channel Creating Market Expansion – Arizton